title: Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity.
abstract: OBJECTIVE
  To determine the effect of reducing insulin secretion on hyperandrogenemia in lean normoinsulinemic women with polycystic ovary syndrome (PCOS) and normal metabolic insulin sensitivity.
  
  
  METHODS
  Transversal assessment at baseline and prospective follow-up of lean PCOS group after 8 days of diazoxide, which reduces insulin secretion, and 1 month of leuprolide, which suppresses LH.
  
  
  METHODS
  Clinical research center of an academic hospital.
  
  
  METHODS
  Nine lean women (body mass index <or=25 kg/m(2)) with PCOS and normal insulin levels, as well as 17 lean healthy women.
  
  
  METHODS
  Lean PCOS women were reassessed after 8 days of diazoxide and after 1 month of leuprolide, which suppresses LH.
  
  
  METHODS
  Androgen levels and insulin-stimulated glucose disposal (metabolic insulin sensitivity), determined by euglycemic-hyperinsulinemic clamp (M-value).
  
  
  RESULTS
  Mean M-value of lean PCOS women (48.5 micromol/kg.min) was similar to lean control subjects (52.9 micromol/kg.min). They also had comparable anthropometric measures, lipids, fibrinogen, and plasminogen activator inhibitor 1. The LH did not change significantly after diazoxide, but was almost suppressed after leuprolide in the PCOS group. Androstenedione decreased significantly after diazoxide and even more after leuprolide. However, free T significantly decreased only after diazoxide in lean PCOS women. Diazoxide also increased SHBG significantly in this group.
  
  
  CONCLUSIONS
  In women with typical PCOS and normal insulin levels and metabolic insulin sensitivity, reducing insulin secretion significantly decreased androgen and increased SHBG levels. These results suggest that insulin contributes to hyperandrogenemia even in PCOS women with normal metabolic insulin sensitivity, which might be due to increased sensitivity of their androgenic insulin pathway.
authors.affiliation: Department of Medicine, Division of Endocrinology, Université de Sherbrooke, Sherbrooke, Quebec, Canada. jp.baillargeon@usherbrooke.ca
authors.forename: Jean-Patrice
authors.initials: JP
authors.lastname: Baillargeon
authors.forename: André
authors.initials: A
authors.lastname: Carpentier
mesh_terms: D000293:Adolescent; D000328:Adult; D000728:Androgens / Q000097:blood*; D000735:Androstenedione / Q000097:blood; D003981:Diazoxide; D005260:Female; D006801:Humans; D007328:Insulin / Q000502:physiology*; D016729:Leuprolide; D007986:Luteinizing Hormone / Q000037:antagonists & inhibitors; D011085:Polycystic Ovary Syndrome / Q000503:physiopathology*; D011446:Prospective Studies; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism; D013739:Testosterone / Q000097:blood; D013851:Thinness / Q000503:physiopathology*
chemical_list: D000728:Androgens; D007328:Insulin; D012738:Sex Hormone-Binding Globulin; D013739:Testosterone; D000735:Androstenedione; D007986:Luteinizing Hormone; D016729:Leuprolide; D003981:Diazoxide